Synthetic Biologics, Inc. (NYSEAMERICAN:SYN – Get Free Report) traded up 1% on Monday . The company traded as high as $1.02 and last traded at $1.02. 57,700 shares traded hands during trading, a decline of 71% from the average session volume of 197,338 shares. The stock had previously closed at $1.01.
Synthetic Biologics Stock Up 1.0 %
The firm has a market cap of $16.16 million, a price-to-earnings ratio of -0.84 and a beta of 1.38.
Hedge Funds Weigh In On Synthetic Biologics
Several institutional investors and hedge funds have recently bought and sold shares of SYN. Jane Street Group LLC bought a new stake in shares of Synthetic Biologics in the 1st quarter worth approximately $80,000. Renaissance Technologies LLC grew its position in shares of Synthetic Biologics by 103.9% in the 2nd quarter. Renaissance Technologies LLC now owns 219,000 shares of the company’s stock worth $47,000 after buying an additional 111,600 shares during the last quarter. Northern Trust Corp grew its position in shares of Synthetic Biologics by 37.1% in the 1st quarter. Northern Trust Corp now owns 336,399 shares of the company’s stock worth $96,000 after buying an additional 91,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Synthetic Biologics in the 3rd quarter worth approximately $55,000. Finally, Vanguard Group Inc. grew its position in shares of Synthetic Biologics by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 5,296,501 shares of the company’s stock worth $1,511,000 after buying an additional 48,102 shares during the last quarter. 74.38% of the stock is currently owned by institutional investors.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
- Five stocks we like better than Synthetic Biologics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- How to Invest in Artificial Intelligence
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- What is an Earnings Surprise?
- The Top 5 Analysts Calls in September
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.